13F Holdings
中文EN

LLY ELI LILLY & Co

Pharmaceutical Preparations · NYSE · SEC CIK 59478 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY45.5%
TTM net income YoY49.8%
TTM EPS YoY50.7%
Revenue 3-yr CAGR39.2%
Net income 3-yr CAGR76.8%

Margins

Gross margin83.6%
Operating margin—
Net margin31.9%
FCF margin—
EBITDA margin—

Returns

ROE86.1%
ROA21.0%
ROIC (approx.)—
Asset turnover0.66x

Leverage & solvency

Liabilities / assets72.8%
Debt / equity1.23x
Current ratio1.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.11x
Accruals ratio-2.3%
Payout ratio21.7%
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$65.18B$45.04B$34.12B$28.54B$28.32B
Cost of revenue$11.05B$8.42B$7.08B$6.63B$7.31B
Gross profit$54.13B$36.62B$27.04B$21.91B$21.01B
R&D expense$13.34B$10.99B$9.31B$7.19B$6.93B
SG&A expense$11.09B$8.59B$7.40B$6.44B$6.43B
Interest expense$895.00M$781.00M$486.00M$331.60M$339.80M
Pretax income$25.73B$12.68B$6.55B$6.81B$6.16B
Income tax$5.09B$2.09B$1.31B$561.60M$573.80M
Net income$20.64B$10.59B$5.24B$6.24B$5.58B
EPS (basic)23.0011.765.826.936.15
EPS (diluted)22.9511.715.806.906.12
Dividends declared per share6.235.404.694.073.53
Weighted avg. shares (diluted)899.30M904.10M903.30M904.62M911.68M
Balance sheet
Cash & equivalents$7.27B$3.27B$2.82B$2.07B$3.82B
Short-term investments—$154.80M$109.10M$144.80M$90.10M
Receivables$17.76B$11.01B$9.09B$6.90B$6.67B
Inventory$13.74B$7.59B$5.77B$4.31B$3.89B
Current assets$55.63B$32.74B$25.73B$18.03B$18.45B
PP&E, net$24.68B$17.10B$12.91B$10.14B$8.99B
Goodwill$5.90B$5.77B$4.94B$4.07B$3.89B
Intangibles$6.52B$6.17B$6.91B$7.21B$7.69B
Total assets$112.48B$78.72B$64.01B$49.49B$48.81B
Current liabilities$35.23B$28.38B$27.29B$17.14B$15.05B
Short-term debt$1.64B$5.12B$6.90B$1.50B$1.54B
Long-term debt$40.87B$28.53B$18.32B$14.74B$15.35B
Total debt$42.50B$33.64B$25.23B$16.24B$16.88B
Total liabilities$85.94B$64.44B$53.14B$38.71B$39.65B
Shareholders' equity$26.54B$14.27B$10.77B$10.65B$8.98B
Net debt$35.23B$30.38B$22.41B$14.17B$13.07B
Cash flow statement
Operating cash flow$16.81B$8.82B$4.24B$7.59B$7.37B
Investing cash flow-$10.97B-$9.30B-$7.15B-$3.76B-$2.87B
Financing cash flow-$2.21B$1.23B$3.50B-$5.41B-$4.13B
Depreciation & amortization$2.00B$1.77B$1.53B$1.52B$1.55B
Stock-based compensation$626.00M$646.00M$629.00M$371.10M$342.80M
Dividends paid$5.38B$4.68B$4.07B$3.54B$3.09B
Share buybacks$4.11B$2.50B$750.00M$1.50B$1.25B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.